ReviewJournal of diabetes science and technology2012
Overview of fluorescence glucose sensing: a technology with a bright future.
Review in Journal of diabetes science and technology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 130 citations in OpenAlex.
- Feasibility of an Orthogonal Redundant Sensor incorporating Optical plus Redundant Electrochemical Glucose Sensing.Journal of diabetes science and technology · 2016Trial
- Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring.Journal of diabetes science and technology · 2016Trial
- Review
- Augmenting ultrasound for continuous glucose monitoring via a wearable acoustically readable microneedle patch.Science advances · 2026Article
- Continuous Glucose Monitoring Systems Can Meet the Challenge of Glucose Management and Beyond in Individuals with Type 2 Diabetes: An Expert Multidisciplinary Position.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Exploring the impact of advanced glycation end products on diabetic salivary gland dysfunctions.Glycoconjugate journal · 2025Review
- Article
- Article
- The performance of a very sensitive glucose sensor developed with copper nanostructure-supported nitrogen-doped carbon quantum dots.RSC advances · 2024Article
- Non-Enzymatic Glucose Sensors Composed of Polyaniline Nanofibers with High Electrochemical Performance.Molecules (Basel, Switzerland) · 2024Article
- Nanotechnology-based Herbal Drug Formulation in the Treatment of Diabetes Mellitus.Current diabetes reviews · 2024Review
- Wearable device for continuous sweat lactate monitoring in sports: a narrative review.Frontiers in physiology · 2024Review
- Article
- Continuous Glucose Monitoring Enabled by Fluorescent Nanodiamond Boronic Hydrogel.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Sugar Molecules Detection via CNanomaterials (Basel, Switzerland) · 2023Article
- Review
- Properties and Applications of Graphene and Its Derivatives in Biosensors for Cancer Detection: A Comprehensive Review.Biosensors · 2022Review
- Wearable electronics for skin wound monitoring and healing.Soft science (Alhambra, Calif.) · 2022Article
- Wearable Smart Contact Lenses for Continual Glucose Monitoring: A Review.Frontiers in medicine · 2022Review
- Products for Monitoring Glucose Levels in the Human Body With Noninvasive Optical, Noninvasive Fluid Sampling, or Minimally Invasive Technologies.Journal of diabetes science and technology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluorescence represents a promising alternative technology to electrochemistry and spectroscopy for accurate analysis of glucose in diabetes; however, no implanted fluorescence glucose assay is currently commercially available. The method depends on the principle of fluorescence, which is the emission of light by a substance after absorbing light. A fluorophore is a molecule that will absorb energy of a specific wavelength and reemit energy at a different wavelength. A fluorescence glucose-sensing molecule can be constructed to increase or decrease in fluorescence from baseline according to the ambient concentration of glucose. A quantum dot is a semiconductor crystal that can serve as a sensor by fluorescing at a desired wavelength or color, depending on the crystal size and materials used. If receptor molecules for glucose can be adsorbed to single-wall carbon nanotubules, then the resulting binding of glucose to these receptors will alter the nanotubes' fluorescence. Fluorescence glucose sensors can provide a continuous glucose reading by being embedded into removable wire-shaped subcutaneous or intravenous catheters as well as other types of implanted structures, such as capsules, microcapsules, microbeads, nano-optodes, or capillary tubes. Fluorescence glucose-sensing methods, which are under development, offer four potential advantages over commercially used continuous glucose monitoring technologies: (1) greater sensitivity to low concentrations of glucose, (2) the possibility of constructing sensors that operate most accurately in the hypoglycemic range by using binding proteins with disassociation constants in this range, (3) less need to recalibrate in response to local tissue reactions around the sensor, and (4) no need to implant either a transmitter or a power source for wireless communication of glucose data. Fluorescence glucose sensors also have four significant disadvantages compared with commercially used continuous glucose monitoring technologies: (1) a damaging foreign body response; (2) a sensitivity to local pH and/or oxygen, which can affect the dye response; (3) potential toxicity of implanted dyes, especially if the implanted fluorophore cannot be fully removed; and (4) the necessity of always carrying a dedicated light source to interrogate the implanted sensor. Fluorescence sensing is a promising method for measuring glucose continuously, especially in the hypoglycemic range. If currently vexing technical and engineering and biocompatibility problems can be overcome, then this approach could lead to a new family of continuous glucose monitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.